查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
化膿性汗腺炎市場:KOL的洞察
市場調查報告書
商品編碼
1769046

化膿性汗腺炎市場:KOL的洞察

KOL Insight - Hidradenitis Suppurativa
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告探討了化膿性汗腺炎 (HS) 治療領域不斷發展變化的前景，並對現有和新興療法進行了全面分析。基於對12位關鍵意見領袖的訪談，報告探討了TNF抑制劑（如修美樂）在生物相似藥興起背景下的關鍵作用、IL-17抑制劑（如優時比的Bimzelx）的廣闊前景、口服JAK抑制劑（如Incyte的povorcitinib）帶來的課題和機遇，以及它們在治療方案中的地位。

對於希望了解不斷變化的治療格局並預測HS管理未來發展的醫藥專業人士而言，這項分析至關重要。

關鍵問題

  • TNF抑制劑（如修美樂和類克）目前如何用於治療化膿性汗腺炎，以及新療法預計會帶來哪些改變？
  • 抗TNF生物相似藥的研發如何影響HS市場的處方行為、可近性和定價？
  • 諾華公司的IL-17A抑制劑Cosentyx的實際應用如何？專家預計其作用將如何改變？
  • 優時比（UCB）的Bimzelx的最新臨床數據與Cosentyx相比如何？預計它們將如何影響HS治療格局？
  • MoonLake Immunotherapeutics的soneloximab在IL-17治療HS中可能發揮什麼作用？
  • Incyte公司的JAK1抑制劑povorcitinib與AbbVie公司的Rinvoq相比如何？在未來的臨床實務中，它們可能如何進行序列分析或合併用藥？
  • 外用JAK抑制劑Opcella在HS治療方案中處於什麼位置？
  • IL-1-αβ 抑制劑和 BTK 抑制劑等替代標靶在 HS 治療中的治療潛力。
  • 在研產品必須達到哪些療效、耐久性和安全性基準才能與現有的 TNF 和 IL-17 抑制劑競爭？
  • 是否有任何後期藥物可以彌補這些差距？

領導品牌

  • Humira(Adalimumab)
  • Remicade(Infliximab)
  • kosentikusu(Secukinumab)
  • bimuzerekkusu(bimekizumabu)
  • sonerokimabu
  • poborushichinibu
  • 磷投手犯規(Upadacitinib)
  • opuserura(rukisorichinibu)
  • ruchikizumabu
  • remiburuchinibu
  • supebigo(supesorimabu)
  • biroberimabu
  • 籠墨最後

部分參與專家名單

  • 多倫多大學醫學院皮膚科教授兼系主任，多倫多女子學院醫院皮膚科系主任
  • 明尼蘇達大學醫學與皮膚科副教授
  • 北卡羅來納州溫斯頓塞勒姆維克森林大學醫學院皮膚病學、病理學和公共衛生科學教授
  • 荷蘭鹿特丹伊拉斯姆斯醫學中心實驗免疫皮膚病學教授
  • 明尼蘇達大學生物醫學科學院臨床教授丹麥哥本哈根
  • 挪威北極大學皮膚病學和性病學教授，挪威博多Nordlandsykehuset皮膚病學主任

研究方法

"治療趨勢" 報告透過對全球領先的關鍵意見領袖 (KOL) 進行深入訪談，探討關鍵疾病領域的當前和未來治療前景。 KOL 的篩選標準非常嚴格，包括其全球聲譽、臨床專業知識以及在治療領域的影響力。每次訪談都配有精心設計的討論指南。這些指南由我們與 KOL 合作開發，並由行業專家進行同行評審，以確保所提問題全面且與當前市場動態相關。在每份報告發布後，我們會持續進行12個月的市場監測，並及時提供來自 KOL 的關於重要新聞事件、市場變化和市場發展的最新消息。

我們的報告有何獨特之處？

FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供深入可行的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察，幫助我們的客戶掌握新興趨勢，並有效應對複雜課題。憑藉廣泛的研究以及來自頂尖專家和關鍵意見領袖 (KOL) 的獨立、公正的見解，我們的報告能夠提供您所需的準確性和可靠性。獨家訪談和數據，以及持續的市場監測，讓您能夠全面了解市場動態。我們的報告涵蓋 40 多個活躍的疾病領域，包括 KOL 洞察和定量醫生調查在內的醫生情報，以及行業專家對醫療事務、數位健康、銷售與行銷、市場准入和其他領域問題的看法，使您能夠做出更明智的數據驅動決策，並在快速變化的行業中保持競爭力。

簡介目錄

This report delves into the evolving landscape of hidradenitis suppurativa (HS) treatment, providing a comprehensive analysis of current and emerging therapies. Based on insights from interviews with 12 KOLs, it explores the pivotal role of TNF inhibitors like Humira amidst the rise of biosimilars, the promising potential of IL-17 inhibitors, such as UCB's Bimzelx, and the challenges and opportunities presented by oral JAK inhibitors, including Incyte's povorcitinib, and their place in the treatment algorithm.

This analysis is crucial for pharmaceutical professionals aiming to navigate the evolving therapeutic landscape and anticipate future developments in HS management.

Key Questions Answered:

  • How are TNF inhibitors like Humira and Remicade currently utilized in hidradenitis suppurativa treatment, and what changes are anticipated with newer therapies?
  • What impact is the rollout of anti-TNF biosimilars having on prescribing behavior, access, and pricing dynamics in the HS market?
  • What is the real-world uptake of Novartis' IL-17A inhibitor Cosentyx, and how do experts expect its role to evolve?
  • How do the latest clinical data for UCB's Bimzelx compare with Cosentyx, and what is its expected impact on the HS treatment landscape?
  • What is the potential role of MoonLake Immunotherapeutics' sonelokimab in the IL-17 treatment landscape for HS?
  • How do Incyte's JAK1 inhibitor povorcitinib and AbbVie's Rinvoq compare, and how might they be sequenced or combined in future practice?
  • Where does the topical JAK inhibitor Opzelura fit into the HS treatment algorithm?
  • What are the therapeutic potentials of alternative targets like IL-1-alpha-beta inhibition and BTK inhibition in HS treatment?
  • What efficacy, durability, and safety benchmarks must pipeline products achieve to compete with established TNF and IL-17 inhibitors?
  • What key unmet needs persist in HS, and are any late-stage agents poised to address these gaps?

Key Brands:

  • Humira (adalimumab)
  • Remicade (infliximab)
  • Cosentyx (secukinumab)
  • Bimzelx (bimekizumab)
  • sonelokimab
  • povorcitinib
  • Rinvoq (upadacitinib)
  • Opzelura (ruxolitinib)
  • lutikizumab
  • remibrutinib
  • Spevigo (spesolimab)
  • vilobelimab
  • orismilast

Partial List of Participating Experts:

  • Professor and Director of the Departmental Division for Dermatology, Department of Medicine at the University of Toronto and Division Head of Dermatology at Women's College Hospital, Toronto
  • Associate Professor of Internal Medicine & Dermatology at the University of Minnesota, MN
  • Professor of Dermatology, Pathology and Public Health Sciences at the Wake Forest University School of Medicine, Winston-Salem, NC
  • Professor in Experimental Immunodermatology, Erasmus MC, Rotterdam, Netherlands
  • Clinical Professor, Department of Biomedical Sciences, University of Copenhagen, Denmark
  • Head Physician, Dermatologist, Nordlandssykehuset Bodo, Professor of Skin and Venereal Diseases, The Arctic University of Norway, Norway

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.